Adalimumab-Aaty

Introduction Overview

Generic Name

adalimumab-aaty

Brand Name

Yuflyma

Dosage Form

Yuflyma Auto-injector, Yuflyma Prefilled Syringe Injection

Drug Class

TNF alfa inhibitors

Pharmacokinetics

Absorption: Adalimumab-aaty, the active component in Yuflyma, is administered via subcutaneous injection, ensuring a gradual and sustained absorption into systemic circulation. After subcutaneous administration, peak plasma concentrations of adalimumab are typically reached within 5 to 7 days. Absorption kinetics may be influenced by injection site, blood flow, and individual patient factors such as body weight and concomitant medications. Clinical studies report bioavailability of adalimumab at approximately 64% following subcutaneous delivery, indicative of substantial systemic availability which correlates with therapeutic efficacy. Patient counseling emphasizes proper injection techniques to optimize absorption.

Distribution: After systemic absorption, adalimumab displays a volume of distribution of approximately 5 to 6 L, consistent with distribution primarily in the vascular and interstitial spaces. Being a large monoclonal antibody (~148 kDa), adalimumab does not cross cellular membranes easily, and distribution into tissues is limited but sufficient for engagement with target TNF molecules in extracellular fluids. Binding to soluble and membrane-bound TNF alters distribution dynamics, potentially sequestering the drug within inflammatory sites. The drug does not significantly cross the blood-brain barrier. Protein binding is inherent due to its antibody nature, but specific plasma protein interactions are not classified as influencing pharmacodynamics.

Metabolism: As a monoclonal antibody, adalimumab undergoes catabolism via proteolytic enzymes ubiquitous in the reticuloendothelial system rather than classical hepatic metabolism. It is degraded into small peptides and amino acids through intracellular lysosomal pathways following receptor-mediated endocytosis or nonspecific uptake. Unlike small molecule drugs, it is not metabolized by cytochrome P450 enzymes, thus reducing potential hepatic drug interactions. Target-mediated drug disposition is a key feature, wherein adalimumab binds TNF-alpha, forming complexes that influence clearance rates.

Elimination: Adalimumab elimination follows nonlinear pharmacokinetics due to saturable binding to TNF. The typical half-life ranges from 10 to 20 days, allowing for biweekly or monthly dosing regimens. Clearance is predominantly through catabolic breakdown to peptides and amino acids rather than renal or hepatic excretion. The elimination half-life and clearance may be affected by the presence of anti-drug antibodies, which can increase clearance and reduce drug concentration and efficacy. The prolonged half-life supports a steady-state concentration after approximately 4 weeks of dosing. There are no significant routes of excretion in urine or feces as intact monoclonal antibodies are not excreted unchanged.

Dosage Forms

Available Dosage Forms:
Yuflyma is furnished in both auto-injector and prefilled syringe formats for subcutaneous injection, designed to provide patients with ease of use and dosing flexibility. The specific formulations include:
- Auto-injector: 40 mg/0.4 mL and 80 mg/0.8 mL
- Prefilled syringe: 20 mg/0.2 mL, 40 mg/0.4 mL, and 80 mg/0.8 mL
These dosage forms facilitate precise dosing suitable for various disease severities and patient needs, with the auto-injector offering convenience for self-administration and improved adherence.

Dosages for Adults and Adolescents:
Dosing regimens are contingent on the condition treated, severity, and patient age. For rheumatoid arthritis and similar autoimmune diseases in adults, doses typically begin with 40 mg every other week administered via subcutaneous injection, with adjustments based on clinical response, potentially increasing to 40 mg weekly in inadequate responders. Juvenile idiopathic arthritis in patients aged 2 years and older follows similar dosing, with frequency and amount tailored to body weight and therapeutic response. For Crohn’s disease and ulcerative colitis, initial loading doses may be higher (e.g., 160 mg at week 0) followed by maintenance dosing of 40 mg every other week.

Specific Patient Populations:
In pediatric populations, dosing is carefully weight-based and condition-specific, using the smallest prefilled syringe volumes suitable for smaller patients. Renal and hepatic impairments generally do not necessitate dose adjustments given the catabolic elimination pathway. In elderly patients, no specific dosage modifications are typically required; however, increased susceptibility to infections warrants careful monitoring. Special populations such as pregnant or breastfeeding women require individual risk-benefit assessment, as monoclonal antibodies can cross the placenta and necessitate neonatal monitoring. Immunization history should be reviewed prior to treatment initiation.

Mechanism Of Action

Yuflyma (adalimumab-aaty) is a recombinant human monoclonal antibody of the IgG1 subtype that specifically targets tumor necrosis factor alpha (TNF-α), a key proinflammatory cytokine involved in mediating inflammatory and immune responses. By binding with high affinity and specificity to both the soluble and membrane-bound forms of TNF-α, Yuflyma effectively blocks its interaction with the TNF receptors p55 and p75 on cell surfaces. This inhibition attenuates the downstream signaling pathways that promote inflammation, cellular infiltration, and tissue destruction characteristic of various autoimmune diseases.

At the cellular level, Yuflyma prevents TNF-α induced activation of nuclear factor-kappa B (NF-κB), leading to decreased expression of adhesion molecules, pro-inflammatory cytokines (such as interleukin-1 and interleukin-6), and metalloproteinases. This cascade effectively reduces recruitment and activation of inflammatory cells like macrophages and T-lymphocytes. Additionally, adalimumab can induce apoptosis of TNF-expressing cells and mediate antibody-dependent cellular cytotoxicity, contributing to reduction of pathogenic immune cell populations.

Clinically, the mechanism of TNF-α blockade results in reduced joint inflammation and slow progression of joint damage in rheumatoid arthritis, decreased bowel inflammation in Crohn’s disease and ulcerative colitis, less skin plaque formation in psoriasis, and overall mitigation of symptoms in ankylosing spondylitis and other conditions. As an interchangeable biosimilar to Humira, Yuflyma demonstrates comparable binding kinetics, immunogenicity profile, and clinical efficacy, confirmed by rigorous analytical characterization and clinical studies.

Comparatively, other TNF inhibitors (etanercept, infliximab) differ structurally and pharmacodynamically but share the overall goal of TNF neutralization. Yuflyma’s fully human monoclonal antibody structure reduces immunogenicity risk relative to chimeric antibodies like infliximab. Research and clinical trials have consistently demonstrated the biosimilarity of Yuflyma to Humira, validating its use as a more cost-effective therapeutic option without compromising safety or efficacy.

Pharmacological Actions

Specific inhibition of tumor necrosis factor alpha (TNF-α), a pivotal proinflammatory cytokine.
Reduction of inflammatory cytokine production including interleukin-1 and interleukin-6.
Suppression of leukocyte adhesion molecule expression, limiting immune cell infiltration.
Induction of apoptosis in pathogenic immune cells expressing TNF-α.
Modulation of immune response to diminish autoimmune tissue damage.
Neutralization of both soluble and membrane-bound TNF-α forms.
Downregulation of nuclear factor-kappa B (NF-κB) activation pathway.
Prevention of cartilage and bone degradation by inhibiting metalloproteinase production.
Anti-inflammatory effects leading to symptom relief in multiple autoimmune diseases.
Immunomodulatory activity without global immunosuppression, enabling targeted therapy.
Comparable pharmacodynamic profile to reference molecule Humira.
Exerts disease-modifying actions by slowing disease progression.
Effects sustained over prolonged dosing intervals due to long half-life.

Therapeutic Or Clinical Uses

Treatment of moderate to severe rheumatoid arthritis in adults, alone or with methotrexate.
Management of moderate to severe polyarticular juvenile idiopathic arthritis in children aged 2 and above.
Therapy for psoriatic arthritis in adult patients, used alone or in combination.
Treatment of ankylosing spondylitis in adults to reduce spinal inflammation and symptoms.
Management of moderate to severe hidradenitis suppurativa in adult patients.
Control of moderate to severe Crohn’s disease in adults and children aged 6 years and older.
Treatment of moderate to severe ulcerative colitis in adult patients.
Therapy for chronic severe plaque psoriasis in adults requiring systemic therapy or phototherapy.
Use in non-infectious intermediate, posterior, and panuveitis in adult patients.
Reduction of inflammation and modulation of immune dysregulation in various autoimmune diseases.
Alternative treatment option in patients non-responsive or intolerant to conventional therapies.
Improvement of quality of life by controlling disease signs and symptoms across multiple indications.
FDA-approved interchangeable biosimilar option to reduce healthcare costs.
Used in combination with other disease-modifying antirheumatic drugs (DMARDs) in complex cases.

Side Or Adverse Effects

Common headaches reported during therapy initiation or ongoing treatment.
Upper respiratory tract infections manifested as cold symptoms, including nasal congestion and sore throat.
Injection site reactions such as redness, bruising, itching, swelling, or rash.
Allergic reactions, including hives, facial swelling, and difficulty breathing, requiring emergency intervention.
Possible increased incidence of serious infections like tuberculosis, sepsis, and opportunistic infections.
Symptoms suggestive of lymphoma or other malignancies including swollen glands, unexplained fever, night sweats, and weight loss.
Exacerbation or new onset psoriasis characterized by raised silvery skin plaques.
Liver dysfunction manifestations such as jaundice, dark urine, and abdominal pain.
Development of lupus-like syndrome presenting with joint pain, chest pain, and photosensitive rash.
Neurological symptoms including numbness, tingling, dizziness, vision changes, and muscle weakness.
Gastrointestinal symptoms like upper abdominal pain radiating to the shoulder.
Increased risk of immunogenicity leading to injection site reactions or decreased drug efficacy.
Potential hematologic abnormalities such as easy bruising or bleeding tendencies.
Increased risk of lymphoma particularly in younger patients with inflammatory bowel disease.
Possible reactivation of hepatitis B infection in carriers.

Precautions

Prior testing for latent tuberculosis is mandatory before initiation and periodically during therapy.
Monitor closely for signs of serious infections; therapy should be withheld if infection develops.
Patients should be up to date with all recommended vaccinations prior to starting treatment; live vaccines are contraindicated during therapy.
Screen for hepatitis B virus and monitor status during treatment due to risk of reactivation.
Use caution in patients with a history of malignancy; weigh risk versus benefit carefully.
Regular blood count and liver function monitoring are recommended to detect potential adverse effects early.
Patients with heart failure should be monitored closely due to potential exacerbation with TNF inhibitors.
Avoid use in patients with known hypersensitivity to adalimumab or any component of the formulation.
Educate patients about the symptoms of infection and malignancy, instructing prompt medical consultation if such arise.
Injection technique training is critical to minimize local adverse events and ensure proper dosing.
Caution in patients with demyelinating diseases or neurological disorders given reports of new or worsening symptoms.
Avoid abrupt discontinuation; follow prescriber’s instructions to prevent disease flares.
Consider adjustment or suspension of therapy in perioperative period to reduce infection risk.
Special vigilance is required in elderly patients with comorbidities, as they may have increased susceptibility to infections.
Pregnancy and breastfeeding risks are not fully established; consultation with healthcare provider is essential.

Warnings

Yuflyma suppresses the immune system, increasing susceptibility to serious and potentially fatal infections.
Prior to initiation, screening for latent or active tuberculosis is required; ongoing vigilance for TB symptoms during therapy is mandatory.
There is an increased risk of malignancies, including lymphoma and hepatosplenic T-cell lymphoma, especially in pediatric and young adult patients.
Live vaccines should not be administered during or shortly after discontinuation of Yuflyma due to compromised vaccine efficacy and risk of infection.
Monitor for the development of serious allergic reactions or anaphylaxis following administration.
Discontinue usage if new or worsening neurological symptoms develop, suggestive of demyelinating disease.
Patients should be instructed about the risk of hepatitis B virus reactivation during treatment.
Use caution in patients with congestive heart failure, as worsening symptoms have been reported during TNF inhibitor therapy.
The possibility of immunogenicity may reduce efficacy or lead to infusion/injection reactions.
Yuflyma must not be given to patients with active infections or sepsis.
Pregnant or nursing mothers should discuss potential risks and benefits with their healthcare provider.
Children and adolescents are at heightened risk of infections and malignancies; thus, close monitoring is warranted.
Patients should notify healthcare providers of any new infections or unexplained symptoms immediately.
Avoid use in patients with known hypersensitivity to any component of the drug formulation.

Contraindication

Known hypersensitivity or allergy to adalimumab-aaty or any excipient components.
Active or severe infections including sepsis, abscesses, and opportunistic infections.
Patients with active tuberculosis or untreated latent TB infections.
Concurrent use with other TNF inhibitors or biologic immunomodulators that are contraindicated.
Patients receiving live vaccines concurrently with Yuflyma treatment.
Severe heart failure (New York Heart Association class III/IV) is contraindicated due to reported exacerbations.
History of demyelinating diseases such as multiple sclerosis.
Known history of lymphoma or other cancers related to TNF inhibitor use without adequate evaluation.
Inability to comply with precautions regarding infection risk monitoring and vaccination status.
Use in pediatric patients outside of FDA-approved indications is generally contraindicated without specialist guidance.
Patients with active hepatitis B virus infection without proper antiviral treatment.
Discontinued doses or insufficient recovery from adverse reactions to prior TNF blocker therapy.
Any condition resulting in severe immunosuppression where the risk of infection outweighs benefit.
Hypersensitivity to latex may be a contraindication depending on the device used for injection.

Drug Interactions

Concomitant administration with other TNF blockers like etanercept, infliximab, or certolizumab is not recommended due to increased risk of serious infections and adverse events.
Combination with immunosuppressive agents such as abatacept or anakinra heightens infection risk and is generally contraindicated.
Azathioprine and 6-mercaptopurine may interact, increasing immunosuppression and the risk of infections or bone marrow suppression.
Potential for altered immune response when used concurrently with vaccines; live vaccines should be avoided.
No significant hepatic enzyme metabolism reduces cytochrome P450 mediated interactions, but careful monitoring is advised during polypharmacy.
Concomitant corticosteroid usage may increase infection risk but is often used in combination under close medical supervision.
Drug interactions with antibiotics or antivirals are rare but clinical vigilance for infection control is essential.
Potential additive immunosuppressive effects when used with methotrexate, necessitating periodic lab monitoring.
Use with drugs inducing or inhibiting proteolytic pathways has not been fully studied but is generally unlikely to impact adalimumab levels.
Herbal supplements with immunomodulatory activity may potentiate effects and require monitoring.
Avoid live vaccinations during and for a period after therapy due to immunosuppression.
Adjustment of concomitant therapies for chronic infections may be needed (e.g., hepatitis B treatment).
Interaction with drugs affecting lymphocyte function may augment immunosuppressive risk.
Patients should inform healthcare providers about all medications, including over-the-counter drugs and supplements.
Drug interaction databases and providers should be consulted regularly due to the evolving pharmacopeia.

Preparations Of The Drug

Yuflyma is supplied as prefilled autoinjectors delivering 40 mg/0.4 mL and 80 mg/0.8 mL concentrations.
Prefilled syringes are available in 20 mg/0.2 mL, 40 mg/0.4 mL, and 80 mg/0.8 mL doses, enabling dose flexibility.
The formulation contains active ingredient adalimumab-aaty, and inactive excipients including acetic acid, glycine, polysorbate 80, sodium acetate, and Water for Injection, USP.
All preparations are intended for subcutaneous injection only.
Yuflyma is supplied refrigerated at 2°C to 8°C and should not be frozen; exposure to freezing results in drug discard.
Prefilled autoinjectors and syringes contain latex components; caution is advised for patients with latex allergy.
Storage permits room temperature exposure up to 77°F (25°C) for a maximum of 30 days with light protection, beyond which the product must be discarded.
The drug presents as a clear to slightly opalescent, colorless to pale yellow solution without visible particles.
Single-use devices designed for safe disposal following injection; sharps container usage is mandated by regulations.
The biosimilar nature requires storage and handling similar to the reference biologic Humira to maintain stability and potency.
Do not shake the solution to avoid protein aggregation and reduced efficacy.
Packaging includes written instructions for injection site rotation and proper administration technique.
All presentations are manufactured by CELLTRION, Inc. and distributed by CELLTRION USA, Inc.
Patient support includes educational materials to ensure understanding of storage and administration parameters.
Lot number and expiration date are provided on packaging; expired products must not be used.